Cardlytics Inc (CDLX) CFO Sells $40,606.05 in Stock

Cardlytics Inc (NASDAQ:CDLX) CFO David Thomas Evans sold 2,505 shares of Cardlytics stock in a transaction that occurred on Friday, March 29th. The shares were sold at an average price of $16.21, for a total transaction of $40,606.05. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

David Thomas Evans also recently made the following trade(s):

  • On Monday, April 15th, David Thomas Evans sold 1,500 shares of Cardlytics stock. The shares were sold at an average price of $15.42, for a total transaction of $23,130.00.
  • On Tuesday, March 26th, David Thomas Evans sold 2,616 shares of Cardlytics stock. The shares were sold at an average price of $15.53, for a total transaction of $40,626.48.
  • On Thursday, March 21st, David Thomas Evans sold 2,584 shares of Cardlytics stock. The shares were sold at an average price of $15.72, for a total transaction of $40,620.48.
  • On Monday, March 18th, David Thomas Evans sold 2,634 shares of Cardlytics stock. The shares were sold at an average price of $15.42, for a total transaction of $40,616.28.
  • On Wednesday, March 13th, David Thomas Evans sold 2,554 shares of Cardlytics stock. The shares were sold at an average price of $15.90, for a total transaction of $40,608.60.

NASDAQ CDLX opened at $14.75 on Friday. Cardlytics Inc has a 52 week low of $9.80 and a 52 week high of $28.29. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.40 and a quick ratio of 2.40.

Cardlytics (NASDAQ:CDLX) last posted its earnings results on Tuesday, March 5th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.11). Cardlytics had a negative return on equity of 92.07% and a negative net margin of 35.20%. The firm had revenue of $47.82 million for the quarter, compared to analyst estimates of $45.32 million. As a group, research analysts forecast that Cardlytics Inc will post -2.06 earnings per share for the current fiscal year.

A number of research analysts have weighed in on the stock. SunTrust Banks reaffirmed a “buy” rating and set a $25.00 price target on shares of Cardlytics in a research report on Wednesday, March 6th. Zacks Investment Research raised shares of Cardlytics from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research report on Wednesday, March 6th. Finally, Bank of America raised shares of Cardlytics from a “neutral” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Tuesday, January 15th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Cardlytics has an average rating of “Buy” and an average target price of $22.86.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Canaan Partners VIII LLC bought a new stake in shares of Cardlytics in the fourth quarter worth $25,647,000. FMR LLC increased its stake in shares of Cardlytics by 68.7% in the third quarter. FMR LLC now owns 3,194,572 shares of the company’s stock worth $79,992,000 after buying an additional 1,300,376 shares during the last quarter. Frontier Capital Management Co. LLC increased its stake in shares of Cardlytics by 105.6% in the fourth quarter. Frontier Capital Management Co. LLC now owns 1,462,777 shares of the company’s stock worth $15,842,000 after buying an additional 751,148 shares during the last quarter. Cannell Capital LLC bought a new stake in shares of Cardlytics in the fourth quarter worth $5,491,000. Finally, Jennison Associates LLC increased its stake in shares of Cardlytics by 58.3% in the fourth quarter. Jennison Associates LLC now owns 1,264,354 shares of the company’s stock worth $13,693,000 after buying an additional 465,855 shares during the last quarter. 80.89% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Cardlytics Inc (CDLX) CFO Sells $40,606.05 in Stock” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/david-thomas-evans-sells-2505-shares-of-cardlytics-inc-cdlx-stock.html.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Further Reading: How to read a candlestick chart

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.